The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rivastigmine Market Research Report 2024
Synopsis
Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
The global Rivastigmine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Rivastigmine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Rivastigmine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Rivastigmine include Novartis, Sun Pharmaceutical, Alvogen, Mylan Pharmaceuticals, Teva, Dr. Reddy's Laboratories, Orchid Healthcare, APOTEX and Alembic Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Rivastigmine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rivastigmine.
Report Scope
The Rivastigmine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rivastigmine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rivastigmine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Sun Pharmaceutical
Alvogen
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Segment by Type
Oral
Transdermal Patch
Segment by Application
Alzheimer's Disease
Parkinson's Disease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rivastigmine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rivastigmine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
The global Rivastigmine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Rivastigmine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Rivastigmine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Rivastigmine include Novartis, Sun Pharmaceutical, Alvogen, Mylan Pharmaceuticals, Teva, Dr. Reddy's Laboratories, Orchid Healthcare, APOTEX and Alembic Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Rivastigmine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rivastigmine.
Report Scope
The Rivastigmine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rivastigmine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rivastigmine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Sun Pharmaceutical
Alvogen
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Segment by Type
Oral
Transdermal Patch
Segment by Application
Alzheimer's Disease
Parkinson's Disease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rivastigmine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rivastigmine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Rivastigmine Market Overview
1.1 Product Overview and Scope of Rivastigmine
1.2 Rivastigmine Segment by Type
1.2.1 Global Rivastigmine Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Transdermal Patch
1.3 Rivastigmine Segment by Application
1.3.1 Global Rivastigmine Market Value by Application: (2024-2030)
1.3.2 Alzheimer's Disease
1.3.3 Parkinson's Disease
1.4 Global Rivastigmine Market Size Estimates and Forecasts
1.4.1 Global Rivastigmine Revenue 2019-2030
1.4.2 Global Rivastigmine Sales 2019-2030
1.4.3 Global Rivastigmine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Rivastigmine Market Competition by Manufacturers
2.1 Global Rivastigmine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Rivastigmine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Rivastigmine Average Price by Manufacturers (2019-2024)
2.4 Global Rivastigmine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rivastigmine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rivastigmine, Product Type & Application
2.7 Rivastigmine Market Competitive Situation and Trends
2.7.1 Rivastigmine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rivastigmine Players Market Share by Revenue
2.7.3 Global Rivastigmine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rivastigmine Retrospective Market Scenario by Region
3.1 Global Rivastigmine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Rivastigmine Global Rivastigmine Sales by Region: 2019-2030
3.2.1 Global Rivastigmine Sales by Region: 2019-2024
3.2.2 Global Rivastigmine Sales by Region: 2025-2030
3.3 Global Rivastigmine Global Rivastigmine Revenue by Region: 2019-2030
3.3.1 Global Rivastigmine Revenue by Region: 2019-2024
3.3.2 Global Rivastigmine Revenue by Region: 2025-2030
3.4 North America Rivastigmine Market Facts & Figures by Country
3.4.1 North America Rivastigmine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Rivastigmine Sales by Country (2019-2030)
3.4.3 North America Rivastigmine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Rivastigmine Market Facts & Figures by Country
3.5.1 Europe Rivastigmine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Rivastigmine Sales by Country (2019-2030)
3.5.3 Europe Rivastigmine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rivastigmine Market Facts & Figures by Country
3.6.1 Asia Pacific Rivastigmine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Rivastigmine Sales by Country (2019-2030)
3.6.3 Asia Pacific Rivastigmine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Rivastigmine Market Facts & Figures by Country
3.7.1 Latin America Rivastigmine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Rivastigmine Sales by Country (2019-2030)
3.7.3 Latin America Rivastigmine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rivastigmine Market Facts & Figures by Country
3.8.1 Middle East and Africa Rivastigmine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Rivastigmine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Rivastigmine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rivastigmine Sales by Type (2019-2030)
4.1.1 Global Rivastigmine Sales by Type (2019-2024)
4.1.2 Global Rivastigmine Sales by Type (2025-2030)
4.1.3 Global Rivastigmine Sales Market Share by Type (2019-2030)
4.2 Global Rivastigmine Revenue by Type (2019-2030)
4.2.1 Global Rivastigmine Revenue by Type (2019-2024)
4.2.2 Global Rivastigmine Revenue by Type (2025-2030)
4.2.3 Global Rivastigmine Revenue Market Share by Type (2019-2030)
4.3 Global Rivastigmine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Rivastigmine Sales by Application (2019-2030)
5.1.1 Global Rivastigmine Sales by Application (2019-2024)
5.1.2 Global Rivastigmine Sales by Application (2025-2030)
5.1.3 Global Rivastigmine Sales Market Share by Application (2019-2030)
5.2 Global Rivastigmine Revenue by Application (2019-2030)
5.2.1 Global Rivastigmine Revenue by Application (2019-2024)
5.2.2 Global Rivastigmine Revenue by Application (2025-2030)
5.2.3 Global Rivastigmine Revenue Market Share by Application (2019-2030)
5.3 Global Rivastigmine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Rivastigmine Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Sun Pharmaceutical
6.2.1 Sun Pharmaceutical Corporation Information
6.2.2 Sun Pharmaceutical Description and Business Overview
6.2.3 Sun Pharmaceutical Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sun Pharmaceutical Rivastigmine Product Portfolio
6.2.5 Sun Pharmaceutical Recent Developments/Updates
6.3 Alvogen
6.3.1 Alvogen Corporation Information
6.3.2 Alvogen Description and Business Overview
6.3.3 Alvogen Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Alvogen Rivastigmine Product Portfolio
6.3.5 Alvogen Recent Developments/Updates
6.4 Mylan Pharmaceuticals
6.4.1 Mylan Pharmaceuticals Corporation Information
6.4.2 Mylan Pharmaceuticals Description and Business Overview
6.4.3 Mylan Pharmaceuticals Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan Pharmaceuticals Rivastigmine Product Portfolio
6.4.5 Mylan Pharmaceuticals Recent Developments/Updates
6.5 Teva
6.5.1 Teva Corporation Information
6.5.2 Teva Description and Business Overview
6.5.3 Teva Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Teva Rivastigmine Product Portfolio
6.5.5 Teva Recent Developments/Updates
6.6 Dr. Reddy's Laboratories
6.6.1 Dr. Reddy's Laboratories Corporation Information
6.6.2 Dr. Reddy's Laboratories Description and Business Overview
6.6.3 Dr. Reddy's Laboratories Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr. Reddy's Laboratories Rivastigmine Product Portfolio
6.6.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.7 Orchid Healthcare
6.6.1 Orchid Healthcare Corporation Information
6.6.2 Orchid Healthcare Description and Business Overview
6.6.3 Orchid Healthcare Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Orchid Healthcare Rivastigmine Product Portfolio
6.7.5 Orchid Healthcare Recent Developments/Updates
6.8 APOTEX
6.8.1 APOTEX Corporation Information
6.8.2 APOTEX Description and Business Overview
6.8.3 APOTEX Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 APOTEX Rivastigmine Product Portfolio
6.8.5 APOTEX Recent Developments/Updates
6.9 Alembic Pharmaceuticals
6.9.1 Alembic Pharmaceuticals Corporation Information
6.9.2 Alembic Pharmaceuticals Description and Business Overview
6.9.3 Alembic Pharmaceuticals Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Alembic Pharmaceuticals Rivastigmine Product Portfolio
6.9.5 Alembic Pharmaceuticals Recent Developments/Updates
6.10 MACLEODS
6.10.1 MACLEODS Corporation Information
6.10.2 MACLEODS Description and Business Overview
6.10.3 MACLEODS Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 MACLEODS Rivastigmine Product Portfolio
6.10.5 MACLEODS Recent Developments/Updates
6.11 Cadila Pharmaceuticals
6.11.1 Cadila Pharmaceuticals Corporation Information
6.11.2 Cadila Pharmaceuticals Rivastigmine Description and Business Overview
6.11.3 Cadila Pharmaceuticals Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Cadila Pharmaceuticals Rivastigmine Product Portfolio
6.11.5 Cadila Pharmaceuticals Recent Developments/Updates
6.12 Aurobindo Pharma
6.12.1 Aurobindo Pharma Corporation Information
6.12.2 Aurobindo Pharma Rivastigmine Description and Business Overview
6.12.3 Aurobindo Pharma Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Aurobindo Pharma Rivastigmine Product Portfolio
6.12.5 Aurobindo Pharma Recent Developments/Updates
6.13 Ajanta Pharma
6.13.1 Ajanta Pharma Corporation Information
6.13.2 Ajanta Pharma Rivastigmine Description and Business Overview
6.13.3 Ajanta Pharma Rivastigmine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Ajanta Pharma Rivastigmine Product Portfolio
6.13.5 Ajanta Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rivastigmine Industry Chain Analysis
7.2 Rivastigmine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rivastigmine Production Mode & Process
7.4 Rivastigmine Sales and Marketing
7.4.1 Rivastigmine Sales Channels
7.4.2 Rivastigmine Distributors
7.5 Rivastigmine Customers
8 Rivastigmine Market Dynamics
8.1 Rivastigmine Industry Trends
8.2 Rivastigmine Market Drivers
8.3 Rivastigmine Market Challenges
8.4 Rivastigmine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
